Business Context and Reporting Period
This Form 8-K was filed by XpresSpa Group, Inc. (trading symbol: XSPA) on March 27, 2020. The filing reports the entry into a Material Definitive Agreement regarding a registered direct offering of securities.
Key Financial Metrics and Transaction Details
- Transaction Type: Registered direct offering of Common Stock and Pre-Funded Warrants.
- Common Stock Issued: 7,895,000 shares at an offering price of $0.20 per share.
- Pre-Funded Warrants Issued: 2,105,000 warrants at an offering price of $0.19 per warrant (exercisable at $0.01 per share).
- Gross Proceeds: Approximately $2.0 million (before deducting fees and expenses).
- Advisory Fees: 8% of aggregate gross proceeds payable to Palladium Capital Advisors, LLC.
- Share Count Impact: Outstanding shares increased from 44,950,030 to an expected 52,846,030 (excluding warrant exercises).
Material Changes Versus Prior Period
The filing does not provide comparative financial performance data (revenue, profit, or cash flow) for the current period versus prior periods. The primary material change is the dilution of existing shareholders due to the issuance of new equity and warrants to raise capital.
Guidance, Outlook, and Risks
- Closing Date: Expected on or about March 30, 2020, subject to customary conditions.
- Use of Proceeds: The filing does not specify the intended use of the $2.0 million in gross proceeds.
- Risks: The document includes standard forward-looking statement disclaimers, noting that actual results may differ materially due to risks discussed in the Company's Form 10-K (filed April 1, 2019) and Form 10-Q (filed November 14, 2019).
- Unusual Items: The inclusion of Pre-Funded Warrants indicates that certain purchasers were restricted from acquiring more than 4.99% (or 9.99% in certain cases) of outstanding Common Stock immediately following the offering.
Important Facts for Investor Verification
- Verify the final closing date and actual net proceeds after deducting the 8% advisory fee and other offering expenses.
- Confirm the extent of shareholder dilution, noting the increase in outstanding shares from ~45 million to ~53 million.
- Review the attached Press Release (Exhibit 99.1) and Securities Purchase Agreement (Exhibit 10.1) for specific terms regarding the Pre-Funded Warrants and any lock-up provisions.
- Check subsequent filings for the actual use of the raised capital, as this 8-K does not specify it.